These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

125 related articles for article (PubMed ID: 15255551)

  • 1. Are plasma insulin-like growth factor I (IGF-I) and IGF-binding protein 3 (IGFBP-3) useful markers of prostate cancer?
    Lopez JB; Sahabudin RM; Chin LP
    Int J Biol Markers; 2004; 19(2):164-7. PubMed ID: 15255551
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Insulin-like growth factor I (IGF-I) and IGF-binding protein-3 in benign prostatic hyperplasia and prostate cancer.
    Khosravi J; Diamandi A; Mistry J; Scorilas A
    J Clin Endocrinol Metab; 2001 Feb; 86(2):694-9. PubMed ID: 11158033
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Serum insulin-like growth factor-I and insulin-like growth factor-binding protein-3 in localized, metastasized prostate cancer and benign prostatic hyperplasia.
    Aksoy Y; Aksoy H; Bakan E; Atmaca AF; Akçay F
    Urol Int; 2004; 72(1):62-5. PubMed ID: 14730168
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Elevated insulin and reduced insulin like growth factor binding protein-3/prostate specific antigen ratio with increase in prostate size in Benign Prostatic Hyperplasia.
    Sreenivasulu K; Nandeesha H; Dorairajan LN; Rajappa M; Vinayagam V
    Clin Chim Acta; 2017 Jun; 469():37-41. PubMed ID: 28300542
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Serum insulin-like growth factor binding protein-3/prostate-specific antigen ratio is a useful predictive marker in patients with advanced prostate cancer.
    Miyata Y; Sakai H; Hayashi T; Kanetake H
    Prostate; 2003 Feb; 54(2):125-32. PubMed ID: 12497585
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Relationship of insulin-like growth factor (IGF) binding protein-3 (IGFBP-3) gene polymorphism with the susceptibility to development of prostate cancer and influence on serum levels of IGF-I, and IGFBP-3.
    Safarinejad MR; Shafiei N; Safarinejad S
    Growth Horm IGF Res; 2011 Jun; 21(3):146-54. PubMed ID: 21536469
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Insulin-like growth factor-binding protein-2 in patients with prostate carcinoma and benign prostatic hyperplasia.
    Ho PJ; Baxter RC
    Clin Endocrinol (Oxf); 1997 Mar; 46(3):333-42. PubMed ID: 9156044
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Insulin-like growth factor (IGF)-I, IGF binding protein-3, and prostate cancer: correlation with Gleason score.
    Correa LL; Neto LV; Lima GA; Gabrich R; Miranda LC; Gadelha MR
    Int Braz J Urol; 2015; 41(1):110-5. PubMed ID: 25928516
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Measurement of insulin-like growth factor axis does not enhance specificity of PSA-based prostate cancer screening.
    Oliver SE; Holly J; Peters TJ; Donovan J; Persad R; Gillatt D; Pearce A; Hamdy FC; Neal DE; Gunnell D
    Urology; 2004 Aug; 64(2):317-22. PubMed ID: 15302487
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Insulin-like growth factor-binding protein-2 in patients with prostate carcinoma and benign prostatic hyperplasia.
    Ho PJ; Baxter RC
    Clin Endocrinol (Oxf); 1997 Feb; 46(2):145-54. PubMed ID: 9135695
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Plasma insulin-like growth factor-I, insulin-like growth factor-binding proteins, and prostate cancer risk: a prospective study.
    Stattin P; Bylund A; Rinaldi S; Biessy C; Déchaud H; Stenman UH; Egevad L; Riboli E; Hallmans G; Kaaks R
    J Natl Cancer Inst; 2000 Dec; 92(23):1910-7. PubMed ID: 11106682
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The correlation between zinc and insulin-like growth factor 1 (IGF-1), its binding protein (IGFBP-3) and prostate-specific antigen (PSA) in prostate cancer.
    Daragó A; Sapota A; Matych J; Nasiadek M; Skrzypińska-Gawrysiak M; Kilanowicz A
    Clin Chem Lab Med; 2011 Oct; 49(10):1699-705. PubMed ID: 21671822
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Serum insulin-like growth factor (IGF)-1 and IGF-binding protein-3 do not correlate with Gleason score or quantity of prostate cancer in biopsy samples.
    Ismail HA; Pollak M; Behlouli H; Tanguay S; Bégin LR; Aprikian AG
    BJU Int; 2003 Nov; 92(7):699-702. PubMed ID: 14616449
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Serum IGF-binding protein-6 and prostate specific antigen in breast cancer.
    Kaulsay KK; Ng EH; Ji CY; Ho GH; Aw TC; Lee KO
    Eur J Endocrinol; 1999 Feb; 140(2):164-8. PubMed ID: 10069662
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Insulin-like growth factor-1 and insulin-like growth factor binding protein-3 for prostate cancer detection in patients undergoing prostate biopsy.
    Ismail A H; Pollak M; Behlouli H; Tanguay S; Begin LR; Aprikian AG
    J Urol; 2002 Dec; 168(6):2426-30. PubMed ID: 12441932
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Levels of insulin-like growth factor I (IGF-I) and IGF binding proteins 2 and 3 in serial postoperative serum samples and risk of prostate cancer recurrence.
    Yu H; Nicar MR; Shi R; Berkel HJ; Nam R; Trachtenberg J; Diamandis EP
    Urology; 2001 Mar; 57(3):471-5. PubMed ID: 11248622
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Insulin-like growth factor I is not a useful marker of prostate cancer in men with elevated levels of prostate-specific antigen.
    Finne P; Auvinen A; Koistinen H; Zhang WM; Määttänen L; Rannikko S; Tammela T; Seppälä M; Hakama M; Stenman UH
    J Clin Endocrinol Metab; 2000 Aug; 85(8):2744-7. PubMed ID: 10946875
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Ratios of IGF-I, IGF binding protein-3, and prostate-specific antigen in prostate cancer detection.
    Stattin P; Stenman UH; Riboli E; Hallmans G; Kaaks R
    J Clin Endocrinol Metab; 2001 Dec; 86(12):5745-8. PubMed ID: 11739433
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Circulating free insulin-like growth factor (IGF)-I, total IGF-I, and IGF binding protein-3 levels do not predict the future risk to develop prostate cancer: results of a case-control study involving 201 patients within a population-based screening with a 4-year interval.
    Janssen JA; Wildhagen MF; Ito K; Blijenberg BG; Van Schaik RH; Roobol MJ; Pols HA; Lamberts SW; Schröder FH
    J Clin Endocrinol Metab; 2004 Sep; 89(9):4391-6. PubMed ID: 15356036
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Serum insulin-like growth factor I/free prostate specific antigen (IGF-I/fPSA) ratio enhances prostate cancer detection in men with total PSA 4.0-10.0 ng/ml.
    Zhigang Z; Jieming L; Su L; Wenlu S
    J Surg Oncol; 2007 Jul; 96(1):54-61. PubMed ID: 17345593
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.